Tryptamine Therapeutics (ASX:TYP) EV-to-EBIT : -2.10 (As of May. 27, 2024)

Tryptamine Therapeutics EV-to-EBIT Chart

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial						-	-1.93	-	-0.50	-

Competitive Comparison of Tryptamine Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Tryptamine Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tryptamine Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's EV-to-EBIT falls into.

Tryptamine Therapeutics EV-to-EBIT Calculation

Tryptamine Therapeutics's EV-to-EBIT for today is calculated as:

Tryptamine Therapeutics's current Enterprise Value is A$4.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tryptamine Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tryptamine Therapeutics  (ASX:TYP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Tryptamine Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Tryptamine Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was A$2.23 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tryptamine Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tryptamine Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description